Shannon L. Maude, MD, PhD

Papers

2015

Qin H, Cho M, Haso W, Zhang L, Tasian SK, Oo HZ, Negri GL, Lin Y, Zou J, Mallon BS, Maude S, Teachey DT, Barrett DM, Orentas RJ, Daugaard M, Sorensen PHB, Grupp SA, Fry TJ. Eradication of B-ALL using chimeric antigen receptor-expressing T cells targeting the TSLPR oncoprotein. Blood. 2015 Jul 30;126(5):629-39.

Maude SL, Dolai S, Delgado-Martin C, Vincent T, Robbins A, Selvanathan A, Ryan T, Hall J, Wood AC, Tasian SK, Hunger SP, Loh ML, Mullighan CG, Wood BL, Hermiston ML, Grupp SA, Lock RB, Teachey DT. Efficacy of JAK/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia. Blood. 2015 Mar 12;125(11):1759-67.

2014

Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, Chew A, Gonzalez VE, Zheng Z, Lacey SF, Mahnke YD, Melenhorst JJ, Rheingold SR, Shen A, Teachey DT, Levine BL, June CH, Porter DL, Grupp SA. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014 Oct 16;371(16):1507-17.

Maude SL, Fitzgerald JC, Fisher BT, Li Y, Huang YS, Torp K, Seif AE, Kavcic M, Walker DM, Leckerman KH, Kilbaugh TJ, Rheingold SR, Sung L, Zaoutis TE, Berg RA, Nadkarni VM, Thomas NJ, Aplenc R. Outcome of pediatric acute myeloid leukemia patients receiving intensive care in the United States. Pediatr Crit Care Med. 2014; 15:112-20.

2013

Teachey DT, Rheingold SR, Maude SL, Zugmaier G, Barrett DM, Seif AE, Nichols KE, Suppa EK, Kalos M, Berg RA, Fitzgerald JC, Aplenc R, Gore L, Grupp SA. Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood. 2013; 121:5154-57.

Posters and Presentations

2018

Bride KL, Vincent TL, Im SY, Aplenc R, Barrett DM, Carroll WL, Carson R, Dai Y, Devidas M, Dunsmore KP, Fuller T, Glisovic-Aplenc T, Horton TM, Hunger SP, Loh ML, Maude SL, Raetz EA, Winter SS, Grupp SA, Hermiston ML, Wood BL, Teachey DT. Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia. Blood. 2018 Mar 1;131(9):995-999. doi: 10.1182/blood-2017-07-794214. Epub 2018 Jan 5.

Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, Bader P, et al. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med. 2018 Feb 1;378(5):439-448. doi: 10.1056/NEJMoa1709866.

2015

Maude SL, Shaw PA, Aplenc R, Barrett DM, Barker CS, Callahan C, Grupp C, Lacey SF, Levine BL, Melenhorst JJ, Motley L, Rheingold SR, Teachey DT, June CH, Grupp SA. Chimeric Antigen Receptor (CAR)-modified T cells Targeting CD19 Induce Sustained Remissions in Children and Young Adults with Relapsed/Refractory ALL. (Oral presentation at the European Hematology Association 20th Annual Meeting, Vienna, Austria, June 2015)

Maude SL, Shaw PA, Aplenc R, Barrett DM, Barker CS, Callahan C, Lacey SF, Levine BL, Melenhorst JJ, Motley L, Rheingold SR, Teachey DT, June CH, Grupp SA. Chimeric Antigen Receptor (CAR)-modified T cells Induce Durable Remissions in Children with Relapsed/Refractory ALL. (Oral presentation at the American Society of Pediatric Hematology/Oncology Annual Meeting, Phoenix, Arizona, May 2015)

2014

Frey NV, Levine BL, Lacey SF, Grupp SA, Maude SL, Schuster SJ, Shaw P, Hwang W-T, Wasik MA, Obstfeld A, Leung M, Shen A, Ericson SG, Melenhorst JJ, June CH, Porter D. Refractory Cytokine Release Syndrome in Recipients of Chimeric Antigen Receptor (CAR) T Cells. Blood 2014; 124:2296. (Poster presentation at the American Society of Hematology 56th Annual Meeting, San Francisco, California, December 2014)

Porter DL, Lacey SF, Hwang W-T, Shaw P, Frey NV, Chew A, Chen F, Kalos M, Gonzalez V, Marcucci KT, Maude SL, Melenhorst JJ, Litchman M, Teachey DT, Shen A, Quintas-Cardamas A, Wood PA, Levine BL, June CH, Grupp SA. Cytokine Release Syndrome (CRS) after Chimeric Antigen Receptor (CAR) T Cell Therapy for Relapsed/Refractory (R/R) CLL. Blood 2014; 124:1983. (Poster presentation at the American Society of Hematology 56th Annual Meeting, San Francisco, California, December 2014)

Grupp SA, Maude SL, Shaw P, Aplenc R, Barrett DM, Callahan C, Chew A, Lacey SF, Levine BL, Melenhorst JJ, Motley L, Rheingold SR, Shen A, Teachey DT, Wood PA, Porter DL, June CH. T cells engineered with a chimeric antigen receptor (CAR) targeting CD19 (CTL019) have long-term persistence and induce durable remissions in children with relapsed, refractory ALL. Blood 2014; 124:380. (Oral presentation at the American Society of Hematology 56th Annual Meeting, San Francisco, California, December 2014)

Maude SL, Dolai S, Delgado-Martin C, Hunger SP, Loh ML, Mullighan CG, Hermiston M, Grupp SA, Lock R, and Teachey DT. Early T-cell Precursor (ETP) acute lymphoblastic leukemia is characterized by aberrant activation of the JAK/STAT pathway and profound responses to ruxolitinib in xenograft models. Congress of the International Society of Paediatric Oncology. (Oral presentation at the SIOP Congress, Toronto, Canada, October 2014)

Maude SL, Dolai S, Delgado-Martin C, Vincent T, Robbins A, Selvanathan  A, Ryan T, Hunger SP, Loh ML, Mullighan CG, Wood B, Hermiston M, Grupp SA, Lock R, and Teachey DT. Targeting the Jak/Stat signaling pathway is highly effective in xenograft models of Early T cell Precursor (ETP) acute lymphoblastic leukemia (ALL). American Association for Cancer Research (AACR) 2014 Annual Meeting. (Oral presentation at the AACR Annual Meeting, San Diego, California, April 2014)

2013

Grupp SA, Frey NV, Aplenc R, Barrett DM, Chew A, Kalos M, Levine BL, Litchman M, Maude SL, Rheingold SR, Shen A, Strait C, Teachey DT, Wood PA, Porter D, June CH. T cells engineered with a chimeric antigen receptor (CAR) targeting CD19 (CTL019) produce significant in vivo proliferation, complete responses and long-term persistence without GVHD in children and adults with relapsed, refractory ALL. Blood 2013; 122:67. (Oral presentation at the American Society of Hematology 55rd Annual Meeting, New Orleans, Louisiana, December 2013)

Grupp SA, Maude SL, Aplenc R, Barrett DM, Kalos M, Levine BL, Litchman M, Rheingold SR, Shen A, Strait C, Teachey DT, Wood PA, June CH. T cells engineered with a chimeric antigen receptor (CAR) targeting CD19 (CTL019) produce complete responses and long-term persistence without GVHD in children with relapsed, refractory ALL. American Association for Cancer Research (AACR), Pediatric Cancer at the Crossroads. (Oral presentation at the AACR Special Conference, Pediatric Cancer at the Crossroads, San Diego, California, November 2013)

Invited Lectures

2015

"Engineered T cell Therapy for Relapsed/Refractory B-ALL," Immune Deficiency/BMT Seminar Series, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, June 2015.

"CD19-Targeted Chimeric Antigen Receptor T cell Therapy for ALL," Tumor Immunology Meets Oncology XI Symposium, Halle, Germany, May 2015.

2014

“New Immunotherapy in Pediatric Oncology,” Jersey Shore University Medical Center Oncology Symposium, Neptune, New Jersey, October 2014.

“Harnessing Cytotoxic T cells to Treat Childhood Leukemia,” iMed Conference, Lisbon, Portugal, October 2014.

“Harnessing the Immune System to Treat Childhood Leukemia,” Hyundai Hope on Wheels Thought Leaders’ Summit, Washington, DC, September 2014.

“CAR-modified T cell Therapy: How do we get there?” International Society of Cell Therapy 2014 Annual Meeting, Paris, France , April 2014.

“Engineered T cell therapy for relapsed/refractory ALL,” Translational Research in Heme/Onc/BMT Seminar Series, Nationwide Children’s Hospital, Columbus, Ohio, March 2014.

“Immunotherapy for Acute Lymphoblastic Leukemia,” Advancing the Health Care of Children, CHOP/Drexel/Hebrew University Collaborative Symposium, The Children’s Hospital of Philadelphia, January 2014.

2013

“Targeting CD19-positive malignancies: chimeric antigen receptor engineered T cells,” Chemotherapy Foundation Symposium, New York, New York, November 2013.

“Preclinical development of targeted therapeutics for high-risk ALL,” The Children’s Oncology Group Fall 2013 Group Meeting, Dallas, Texas, October 2013.

“Highly active cell therapy of leukemia,” The Children’s Oncology Group Fall 2013 Group Meeting, Dallas, Texas, October 2013.

“Identifying biomarkers to predict sensitivity to JAK inhibitors,” The Children’s Oncology Group Fall 2013 Group Meeting, Dallas, Texas, October 2013.